Clinical Research Directory
Browse clinical research sites, groups, and studies.
Atomized Intranasal Ketorolac at 30 mg Versus 20 mg for the Treatment of Acute Pain in the Emergency Department
Sponsor: Tehran University of Medical Sciences
Summary
This study aims to compare the analgesic effectiveness and side effects of intranasal ketorolac at 30 mg Versus 20 mg for the Treatment of Acute moderate and severe Pain in the Emergency Department.
Official title: Atomized Intranasal Ketorolac at 30 mg Versus 20 mg for the Treatment of Acute Pain in the Emergency Department: A Randomized Non-inferiority Trial
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2026-10-10
Completion Date
2027-05-01
Last Updated
2026-09-16
Healthy Volunteers
No
Interventions
20mg intranasal ketorolac
20 mg (1cc) ketorolac will be administered intranasally using mucosal atomizer. Half dose (0.5 cc) in each nostril
30mg Intranasal Ketorolac
30 mg (1cc) ketorolac will be administered intranasally using mucosal atomizer. Half dose (0.5 cc) in each nostril